Compare PepsiCo, Inc. (PEP) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PepsiCo, Inc. vs Summit Therapeutics Inc — how do they compare? PepsiCo, Inc. trades at $135.84 (market cap $184.26B), while Summit Therapeutics Inc trades at $14.78 (market cap $11.34B). The key difference: PepsiCo, Inc. is far larger — about 16.2× Summit Therapeutics Inc's market cap, and PepsiCo, Inc. pays a 4.39% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| PEP | SMMT | |
|---|---|---|
Market Cap | $184.26B | $11.34B |
Sector | Consumer Staples | Health |
52-Week High | $170.44 | $29.32 |
52-Week Low | $134.98 | $13.05 |
Enterprise Value | $226.76B | $10.76B |
Dividend Yield | 4.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PepsiCo (PEP) trades at $134.98, down 0.35% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported revenue of $93.93B in 2025 with a net income margin of 10.78%, and it has beaten EPS estimates in the last three quarters. Recent news highlights price cuts on snacks like Doritos after consumer pushback and the termination of a music festival sponsorship.
The outlook is mixed: analyst consensus is a buy with a $158.79 price target, but near-term risks include competitive pressures and execution of the North American turnaround. Earnings growth and margin expansion from cost initiatives remain key catalysts for upside, though high valuation ratios and debt levels warrant caution.
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting a bearish technical trend amid negative profitability. The company reported a net loss of $1.08 billion for 2025, with deeply negative ROE and ROA, though a recent asset sale and positive clinical trial data for its oncology candidate provide some operational catalysts. Cash flow remains volatile, with net cash flow turning negative in 2026 projections.
The investment case is binary, hinging on the success of ivonescimab. While analyst consensus is bullish with a $15.57 price target, high volatility and ongoing fiduciary investigations pose significant risks. The stock offers high-reward potential for risk-tolerant investors betting on clinical success, but fundamental weaknesses and cash burn necessitate caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
